Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hair Loss/Baldness Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss

NCT00151515
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
minoxidil
Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
15 Years to 49 Years · Male only
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Vallejo, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 2, 2026, 2:25 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012)

NCT01451047
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Oct 2, 2026, 2:25 PM EDT
Completed Not applicable Interventional

Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss

NCT06149221
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
NTAP
Device
Lead sponsor
Dr. Peter C. Friedman
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 2, 2026, 2:25 PM EDT
Recruiting Not applicable Interventional

Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors

NCT04764357
View directory record Official record
Conditions
Alopecia
Interventions
Paxman Scalp Cooling System, Alopecia Assessments, Patient Reported Outcomes Questionnaires
Device · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
7 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 2, 2026, 2:25 PM EDT
Completed Not applicable Interventional

Efficacy and Tolerability of a Scalp Serum

NCT07500623
View directory record Official record
Conditions
Hair Thinning
Interventions
Scalp Serum
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 2, 2026, 2:25 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

NCT05398809
View directory record Official record
Conditions
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
Interventions
Ruxolitinib
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 2, 2026, 2:25 PM EDT
Completed Not applicable Interventional

Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment

NCT02591355
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Autologous Platelet Rich Plasma, Saline solution injection
Device
Lead sponsor
Regen Lab SA
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 2, 2026, 2:25 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931)

NCT01669746
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured mixed population of dermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
7
States / cities
Tucson, Arizona • Santa Rosa, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 2, 2026, 2:25 PM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

NCT02676310
View directory record Official record
Conditions
Alopecia, Alopecia, Androgenetic, Baldness
Interventions
Bimatoprost
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Austin, Texas • College Station, Texas • Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 2, 2026, 2:25 PM EDT
Recruiting Phase 2 Interventional

A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

NCT07533006
View directory record Official record
Conditions
Alopecia Areata
Interventions
LY4005130, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Fremont, California • Northridge, California • Santa Clarita, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 2, 2026, 2:25 PM EDT
Completed Not applicable Interventional Results available

STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia

NCT02503852
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
Puregraft System, Celution System, Kerastem Therapy, Liposuction
Device · Procedure
Lead sponsor
Kerastem Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Highland Park, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 2, 2026, 2:25 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

PAI-1 Expression in Non-scarring Hair Loss

NCT02548689
View directory record Official record
Conditions
Androgenetic Alopecia, Telogen Effluvium, Alopecia Areata
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 2, 2026, 2:25 PM EDT
Active, not recruiting Phase 2 Interventional

Use of Botulinum Toxin in the Treatment of Androgenic Alopecia

NCT05456087
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
incobotulinumtoxin A
Drug
Lead sponsor
Zel Skin and Laser Specialists
Other
Eligibility
22 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Edina, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 2, 2026, 2:25 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

NCT01904721
View directory record Official record
Conditions
Alopecia, Alopecia, Androgenetic, Baldness
Interventions
Bimatoprost Solution 1, Bimatoprost Solution 2, Bimatoprost Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Fridley, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 2, 2026, 2:25 PM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

NCT07146022
View directory record Official record
Conditions
Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia, Hair Loss
Interventions
VDPHL01 QD, Placebo, VDPHL01 BID
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 2, 2026, 2:25 PM EDT
Completed Phase 2 Interventional Results available

A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

NCT02503137
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Topical SM04554 solution, Topical vehicle solution
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Clinton Township, Michigan • Cleveland, Ohio • College Station, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 2, 2026, 2:25 PM EDT
Not yet recruiting Early Phase 1 Interventional

Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia

NCT03474718
View directory record Official record
Conditions
Androgenic Alopecia
Interventions
Platelet-rich Plasma Left Side, Platelet-rich Plasma Right Side
Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 2, 2026, 2:25 PM EDT
Completed Not applicable Interventional Results available

Scalp Cooling to Prevent Hair Loss in Patients Undergoing Stem Cell Transplantation for Multiple Myeloma

NCT05961215
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Penguin Cold Cap
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 2, 2026, 2:25 PM EDT
Enrolling by invitation Not applicable Interventional

Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair

NCT07221773
View directory record Official record
Conditions
Hair Thinning
Interventions
XVIE
Other
Lead sponsor
Restore Biologics Holdings, Inc. dba Xtressé
Industry
Eligibility
28 Years to 65 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Maitland, Florida • Marriottsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 2, 2026, 2:25 PM EDT
Not listed Phase 2 Interventional

Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants

NCT05865041
View directory record Official record
Conditions
Alopecia Areata
Interventions
Farudodstat, Placebo
Drug
Lead sponsor
ASLAN Pharmaceuticals
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Birmingham, Alabama • Fountain Valley, California • Santa Ana, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 2, 2026, 2:25 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)

NCT05914805
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
Clascoterone 5% solution, Vehicle solution
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
18 Years and older · Male only
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Scottsdale, Arizona • Hollywood, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 2, 2026, 2:25 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors

NCT05778825
View directory record Official record
Conditions
Survivors of Childhood Cancer, Alopecia
Interventions
Oral Minoxidil, Placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
6 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 2, 2026, 2:25 PM EDT
Completed No phase listed Observational

Minoxidil Response Testing in Males With Androgenetic Alopecia

NCT02198261
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
5% minoxidil topical foam
Drug
Lead sponsor
Applied Biology, Inc.
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Tucson, Arizona • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 2, 2026, 2:25 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

NCT01325337
View directory record Official record
Conditions
Alopecia, Alopecia, Androgenetic, Baldness
Interventions
bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C, bimatoprost vehicle solution, minoxidil 5% solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 2, 2026, 2:25 PM EDT